| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.13▼ | 1.13▼ | 1.13▼ | 1.24▼ | 1.58▼ |
| MA10 | 1.13▼ | 1.14▼ | 1.16▼ | 1.44▼ | 1.68▼ |
| MA20 | 1.13▼ | 1.16▼ | 1.20▼ | 1.62▼ | 1.82▼ |
| MA50 | 1.15▼ | 1.23▼ | 1.35▼ | 1.73▼ | 2.37▼ |
| MA100 | 1.18▼ | 1.38▼ | 1.56▼ | 1.84▼ | 2.95▼ |
| MA200 | 1.23▼ | 1.58▼ | 1.69▼ | 2.41▼ | 7.19▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.001▲ | 0.001▲ | 0.002▲ | -0.066▼ | -0.025▼ |
| RSI | 34.187▼ | 20.940▼ | 12.492▼ | 20.426▼ | 32.642▼ |
| STOCH | 47.222 | 18.926▼ | 14.472▼ | 5.037▼ | 30.517 |
| WILL %R | -100.000▼ | -94.444▼ | -96.429▼ | -97.353▼ | -98.131▼ |
| CCI | -117.949▼ | -80.507 | -113.969▼ | -122.770▼ | -291.934▼ |
|
Friday, September 11, 2026 08:10 AM
Novartis AG (NYSE:NVS) has suffered a major setback after its experimental drug del-desiran failed a late-stage trial for myotonic dystrophy type 1, a rare muscle-wasting disease with no approved ...
|
|
Friday, September 11, 2026 05:30 AM
Novartis AG’s (NYSE:NVS) pelacarsen failed an important test. Although the experimental medicine lowered lipoprotein(a), or Lp(a), it did not produce a statistically significant reduction in ...
|
|
Tuesday, September 08, 2026 03:26 AM
Novartis (NYSE:NVS) said on Tuesday that its experimental treatment for myotonic dystrophy type 1, delpacibart etedesiran, did not meet the primary endpoint of a Phase III clinical trial. The global ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 11/09/26 | 1.20 | 1.2307 | 1.10 | 1.12 | 1,889,386 |
| 10/09/26 | 1.21 | 1.26 | 1.17 | 1.19 | 1,331,968 |
| 09/09/26 | 1.31 | 1.32 | 1.22 | 1.22 | 1,741,008 |
| 08/09/26 | 1.39 | 1.3981 | 1.30 | 1.30 | 1,914,361 |
| 04/09/26 | 1.40 | 1.44 | 1.375 | 1.39 | 1,527,582 |
| 03/09/26 | 1.65 | 1.6849 | 1.32 | 1.38 | 7,221,123 |
| 02/09/26 | 1.71 | 1.759 | 1.69 | 1.70 | 456,685 |
| 01/09/26 | 1.73 | 1.73 | 1.67 | 1.69 | 456,947 |
| 31/08/26 | 1.72 | 1.7845 | 1.70 | 1.72 | 423,319 |
| 28/08/26 | 1.78 | 1.83 | 1.71 | 1.72 | 498,121 |
|
|
||||
|
|
||||
|
|